- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02083068
Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
This study is a prospective controlled, blinded clinical trial, designed to establish the protective efficacy induced by the vaccine PvCSP between human volunteers with and without history of malaria.
Study subjects
This study will require the involvement of two types of volunteers:
- Parasite donors: 5-15 P. vivax-infected patients who will serve as parasites donors for experimental infection of mosquitoes, who will be enrolled in the endemic area.
- Volunteers for immunization: Two other groups of volunteers will be immunized with the vaccine PvCSP. A group of 16 people without previous exposure to malaria (naive) and another 16 people with a history of previous malaria infection (pre-immune).
Methodology Recruitment of infected patients: Parasite donors will be recruited among P. vivax infected patients attending a diagnostic center in the endemic area.
Infection of mosquitoes Blood from donors will be used to feed three days old mosquitoes by artificial membrane feeding technique. At day 7 a sample of mosquitoes will be examined to determine the degree of infection by dissection of the mosquito gut. On day 14, a small amount of mosquitoes with a good degree of infectivity will be used to infect challenged volunteers.
Recruitment of pre-immune and naive volunteers: Volunteers for the immunization stage will be recruited both in the city of Cali, non-endemic region, and in Buenaventura, a malaria endemic region, through various activities such as conferences, meetings and other means approved by the IRB like posters and flyers.
Immunization: Volunteers will be immunized with the vaccine (n=16) or placebo (n=16).
Follow Up Volunteers will be under medical vigilance during the first hour following the immunization to detect any adverse reaction. After the first hour period a medical exam will be made. Eight hours after immunization, each volunteer will be telephoned to assess physical condition. Any adverse event (AE) will be registered.
Subsequent follow up will be made on the day next to immunization and 1 or 2 weeks before the next immunization by a new clinical evaluation and AE report. Volunteers will be educated to contact the research staff at any moment.
Infection of volunteers Immunized volunteers will be challenged on day ~150 of the study, 1 month after the third immunization by the bite of 3±1 infected mosquitos. The "feeding cage" will be placed on the forearm of a volunteer for 10 minutes, allowing that the feeding window, wich will be covered by a mesh surface be placed against the volunteer's skin.
Volunteers will be educated about the signs and symptoms of malaria and they will have a daily telephone contact during the first 6 days.
Between days 7 and 23 the volunteers will be asked to go to the Clinical Trials Unit daily in order to establish the presence or absence of disease through thick blood smear and samples will be collected for retrospective real time PCR P. vivax.
From day 23 until day 31, volunteers will receive physical and laboratory evaluation every other day and will have daily telephone contact.
Once the patients present signs and symptoms of the disease curative treatment will be immediately provided, and 15 ml of blood will be drawn, which will be used for immune response assessment.
If the volunteers do not develop the disease during the follow-up period, on day 31 they will be given antimalarial treatment.
Treatment Volunteers will be treated with antimalarial drugs approved by the Colombian Ministry of Social Protection: chloroquine (three (3) doses: 600 mg initially, followed by 450mg at 24, and 48 hours), associated with primaquine (30mg/día) for 14 days. All the volunteers will be asked to return two weeks after starting treatment for a thick blood smear test to ensure cure of malaria.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Valle Del Cauca
-
Cali, Valle Del Cauca, Kolumbia
- Malaria Vaccine and Drug Development Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Naïve group
Healthy men and women aged 18-45 years. Signing freely and voluntary informed consent , accompanied by two witnesses who also sign.
Not have a history of malaria infection. For women, use of adequate contraception from the star restriction to be lifted by a doctor for contraception study. Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco ,Urabá and Bajo Cauca) .
Be reachable by phone throughout the study period. Being Duffy positive ( Fy +) . Levels of hemoglobin ( Hb) > 11 g / dl. Availability to participate during the period in which they develop the study. Do not be participating in another clinical study
2. Preimmune group
Healthy men and women aged 18-45 years. Signing freely and voluntary informed consent , accompanied by two witnesses who also sign .
Having a history of infection (s ) and serological tests for malaria positive for P. vivax.
For women, use adequate contraception from the start restriction to be lifted by a doctor for contraception study .
Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco Urabá and Bajo Cauca) .
Be reachable by phone throughout the study period. Availability to participate during the period in which they develop the study.
3. Voluntary blood donors
- Healthy men and women aged 18-45 years.
- Be positive diagnosis of P. vivax determined by thick smear examination .
- The patient must not have circulating malaria parasites such as P. falciparum or P. malariae .
- Have a parasitemia ≥ 0.1 %. by thick smear .
- Hb ≥ 9 g / dL at the time of diagnosis of malaria.
- The patient must have the capacity to provide informed consent freely and voluntarily . Should be illiterate may assert its decision to participate by putting their fingerprint in the format consent. Minors who are between 15 and 17 and wishing to participate must sign the informed consent and one of its Parents must sign the informed consent, accompanied by 2 witnesses who also sign
Exclusion Criteria:
Step 1
- Negative IFAT (< 1:20) for P. vivax on screening tests
- Other criteria used in the case of naive volunteers, except a history of having lived in an endemic area for the past 6 months.
Step 2 Patients that have chronic or acute disease, different from malaria by P. vivax.
Having a history of disease or clinical conditions that according to medical criteria might increase significantly the risk related with participation on this study Hemoglobin levels <9 g/dL at the time of recruitment Have received antimalarial treatment before the diagnosis
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Podstawowa nauka
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Experimental
10 individuals per sub- group to be immunized with the Vaccine PvCS N+C at month 0 and the Vaccine PvCS N+C+R at months 2 and 6
|
Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015
At month 2 and 6
Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015,
at month 0
|
Komparator placebo: Control
six individuals for each sub- group to be immunized with placebo SSN Montanide ISA-51
|
SSN Montanide ISA-51 1 mL
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Protective efficacy against P. vivax infection on volunteers exposed to infected mosquito bites
Ramy czasowe: Thirty days after the last immunization
|
Vaccine protective efficacy against P. vivax infection on volunteers exposed to infected mosquito bites
|
Thirty days after the last immunization
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Evolution of antibody titers
Ramy czasowe: At months 0, 2, 4 and 6 of the trial
|
Follow up every 2 months (month 0, 2, 4 and 6) until the end of the trial will be done to assess the evolution of P. vivax antibody titers.
|
At months 0, 2, 4 and 6 of the trial
|
Specific cytokine induction
Ramy czasowe: At months 0, 2, 4 and 6 of the trial
|
Specific cytokine induction will be measured by IFN- γ, TNF-α, IL-2; IL- 4, IL-6, IL-10
|
At months 0, 2, 4 and 6 of the trial
|
Changes on vaccine biological security
Ramy czasowe: On the day next to immunization and 1 or 2 weeks before the next immunization
|
Changes on vaccine biological security will be measured by renal, hepatic and hematologic function and pregnancy test.
|
On the day next to immunization and 1 or 2 weeks before the next immunization
|
Antibody functionality in vitro through inhibition of sporozoite invasion (ISI) to Hep-G2 cells.
Ramy czasowe: Every 2 months
|
Antibody functionality will be tested in vitro through essays of inhibition of sporozoite invasion (ISI) to Hep-G2 cells.
|
Every 2 months
|
Vaccine-induced protection for P. vivax
Ramy czasowe: 28 days after mosquito bites
|
Vaccine-induced protection for P. vivax will be assessed by pre-patent period onset after infected mosquito bites exposure
|
28 days after mosquito bites
|
Współpracownicy i badacze
Publikacje i pomocne linki
Publikacje ogólne
- Herrera S, Solarte Y, Jordan-Villegas A, Echavarria JF, Rocha L, Palacios R, Ramirez O, Velez JD, Epstein JE, Richie TL, Arevalo-Herrera M. Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):4-11. doi: 10.4269/ajtmh.2011.09-0498.
- Arevalo-Herrera M, Gaitan X, Larmat-Delgado M, Caicedo MA, Herrera SM, Henao-Giraldo J, Castellanos A, Devaud JC, Pannatier A, Onate J, Corradin G, Herrera S. Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine. Nat Commun. 2022 Mar 25;13(1):1603. doi: 10.1038/s41467-022-29226-3.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 2304-493-26202
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst i inni współpracownicyRekrutacyjnyMalaria Plasmodium Falciparum | Malaria Plasmodium VivaxLaotańska Republika Ludowo-Demokratyczna
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanZakończonyVivax Malaria | Nieskomplikowana malaria FalciparumAfganistan
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... i inni współpracownicyZakończonyMalaria | Vivax Malaria | Falciparum MalariaEtiopia, Bangladesz, Indonezja
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaZakończonyMalaria Plasmodium Falciparum | Malaria Plasmodium VivaxPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...ZakończonyMalaria Plasmodium Falciparum | Malaria Plasmodium VivaxIndonezja
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...ZakończonyVivax Malaria | Falciparum MalariaIndonezja
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... i inni współpracownicyZakończonyMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...ZakończonyVivax Malaria | Falciparum MalariaIndonezja
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst i inni współpracownicyRekrutacyjnyMalaria Plasmodium Falciparum | Malaria Plasmodium VivaxTajlandia
-
U.S. Army Office of the Surgeon GeneralU.S. Army Medical Research and Development Command; Military Infectious Diseases...ZakończonyFalciparum Malaria | Nieskomplikowana malariaKenia, Tajlandia
Badania kliniczne na Vaccine PvCS N+C+R
-
Malaria Vaccine and Drug Development CenterAsoclinic Inmunología Ltda.; Centro médico ImbanacoZakończony
-
TidalSenseNational Institute for Health Research, United Kingdom; Innovate UKZakończonyZdrowy | Rozstrzenie oskrzeli | Niedokrwistość | Astma | Rak płuc | Śródmiąższowa choroba płuc | POChP | Długi COVID | Choroba górnych dróg oddechowych | Zastoinowa niewydolność sercaZjednoczone Królestwo
-
CHDI Foundation, Inc.Universitaire Ziekenhuizen KU LeuvenZakończony
-
WockhardtZakończonyCukrzyca typu IStany Zjednoczone, Indie
-
Universidad Nacional Autonoma de MexicoRekrutacyjnyInterwencja teleneuropsychologiczna u bezobjawowych pacjentów seropozytywnych z HIV: N&C NeuroChangeTelerehabilitacja | Neuropsychologia | Demencja HIVMeksyk
-
University of North Carolina, Chapel HillWakeMed Health and HospitalsZakończonyCiąża | Cukrzyca insulinoniezależnaStany Zjednoczone
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... i inni współpracownicyRekrutacyjnyKardiomiopatia | Amyloidoza, pierwotnaStany Zjednoczone
-
Omaima Mossad Mahmoud AL-SherbiniZakończonyBól, pooperacyjny | Recesja dziąseł | Zadowolenie pacjenta | Witryna darczyńców | Otwarta rana podniebienia bez komplikacji | Bezpłatne przeszczepy dziąseł | Wady śluzówkowo-dziąsłoweEgipt
-
Children's Oncology GroupNational Cancer Institute (NCI)ZakończonyMięsak | Nowotwory mózgu i ośrodkowego układu nerwowego | Nerwiak zarodkowy : neuroblastomaStany Zjednoczone, Kanada, Portoryko, Holandia, Australia, Nowa Zelandia, Szwajcaria
-
Indiana University School of MedicineZakończonyZapobieganie infekcjomStany Zjednoczone